Low molecular weight heparin vs unfractionated heparin: Dialysis vascular access thrombosis Median
Low molecular weight heparin showed no clear difference in dialysis vascular access thrombosis Median compared with unfractionated heparin (low certainty).
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Low molecular weight heparin vs unfractionated heparin Dialysis vascular access thrombosis Median · adults with kidney failure treated with long‐term HD Low molecular weight heparin showed no clear difference in dialysis vascular access thrombosis Median compared with unfractionated heparin (low certainty). Anticoagulation for people receiving long‐term haemodialysis (2024) · Cochrane Headline outcomes only | RR 0.2 [0.01, 3.7] | 2 studies · 45 participants | Low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Anticoagulation for people receiving long‐term haemodialysis 2024 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.